Āé¶¹Ö±²„

This internet browser is outdated and does not support all features of this site. Please switch or upgrade to a to display this site properly.

Curtin designs unique microcapsules for people with type-1 diabetes

Copy Link

Āé¶¹Ö±²„ researchers are a step closer to establishing a way for people with type-1 diabetes to introduce insulin into the body without the need for injections, through the development of a unique microcapsule.

People with type-1 diabetes, a condition where the immune system destroys cells in the pancreas, generally have to inject themselves with insulin daily and test glucose levels multiple times a day.

Dr Hani Al-Salami, Curtin’s School of Pharmacy, is leading the collaborative project using cutting-edge microencapsulation technologies to design and test whether microcapsules are a viable alternative treatment for people with type-1 diabetes.

ā€œSince 1921, injecting insulin into muscle or fat tissue has been the only treatment option for patients with type-1 diabetes,ā€ Dr Al-Salami said.

ā€œThe ideal way to treat the illness, however, would be to have something, like a microcapsule, that stays in the body and works long-term to treat the uncontrolled blood glucose associated with diabetes.ā€

The microcapsule contains pancreatic cells which can be implanted in the body and deliver insulin to the blood stream.

ā€œWe hope the microcapsules might complement or even replace the use of insulin, in the long-term but we are still a way off. Still, the progress is encouraging and quite positive for people with type-1 diabetes,ā€ Dr Al-Salami said.

Researchers said the biggest challenge in the project to date had been creating a microcapsule that could carry the cells safely, for an extended period of time, without causing an unwanted reaction by the body such as inflammation or graft failure.

ā€œWe are currently carrying out multiple analyses examining various formulations and microencapsulating methods, in order to ascertain optimum engineered microcapsules capable of supporting cell survival and functionality,ā€ Dr Al-Salami said.

The research was conducted in partnership with the University of Western Australia.

Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis outlines the research and was published in Biotechnology Progress. It can be accessed via

Copy Link